Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Vaccine. 2006 Mar 10;24(11):1880-8. doi: 10.1016/j.vaccine.2005.10.036. Epub 2005 Oct 28.
Vaccine. 2006.
PMID: 16300869
Development of optimized cryptic peptides for immunotherapy.
Menez-Jamet J, Kosmatopoulos K.
Menez-Jamet J, et al.
IDrugs. 2009 Feb;12(2):98-102.
IDrugs. 2009.
PMID: 19204883
Review.
Item in Clipboard
Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J, Kosmatopoulos K, Georgoulias V, Mavroudis D.
Vetsika EK, et al. Among authors: menez jamet j.
Cancer Immunol Immunother. 2012 Feb;61(2):157-168. doi: 10.1007/s00262-011-1093-4. Epub 2011 Aug 20.
Cancer Immunol Immunother. 2012.
PMID: 21858533
Free PMC article.
Item in Clipboard
A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
Gallou C, Rougeot A, Graff-Dubois S, Kosmatopoulos K, Menez-Jamet J.
Gallou C, et al. Among authors: menez jamet j.
Oncotarget. 2016 Sep 13;7(37):59417-59428. doi: 10.18632/oncotarget.11086.
Oncotarget. 2016.
PMID: 27506946
Free PMC article.
Item in Clipboard
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.
Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K.
Menez-Jamet J, et al.
Ann Transl Med. 2016 Jul;4(14):266. doi: 10.21037/atm.2016.05.15.
Ann Transl Med. 2016.
PMID: 27563653
Free PMC article.
Review.
Item in Clipboard
Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in "Immune Desert" NSCLC.
Pateras IS, Kotsakis A, Avgeris M, Baliou E, Kouroupakis P, Patsea E, Georgoulias V, Menez-Jamet J, Kinet JP, Kosmatopoulos K.
Pateras IS, et al. Among authors: menez jamet j.
Cancers (Basel). 2021 Apr 1;13(7):1658. doi: 10.3390/cancers13071658.
Cancers (Basel). 2021.
PMID: 33916194
Free PMC article.
Item in Clipboard
A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics.
Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell R, Rossi A, Menez-Jamet J, Iché M, Kosmatopoulos K, Gridelli C.
Georgoulias V, et al. Among authors: menez jamet j.
Clin Lung Cancer. 2013 Jul;14(4):461-5. doi: 10.1016/j.cllc.2013.02.001. Epub 2013 May 4.
Clin Lung Cancer. 2013.
PMID: 23647738
Clinical Trial.
Item in Clipboard
Cite
Cite